Latest Tissue plasminogen activator Stories
REHOVOT, Israel, June 2, 2014 /PRNewswire/ -- D-Pharm Ltd.
UVA's stroke program has received the highest quality award from the American Heart Association. Charlottesville,VA (PRWEB) April 24, 2014 The American
Administering a clot-dissolving drug to stroke victims quickly — ideally within the first 60 minutes after they arrive at a hospital emergency room — is crucial to saving their lives, preserving their brain function and reducing disability.
Using an ambulance that included a computed tomography (CT) scanner, point-of-care laboratory, telemedicine connection and a specialized prehospital stroke team resulted in decreased time to treatment for ischemic stroke.
In a study that included more than 71,000 stroke patients, implementation of a quality initiative was associated with improvement in the time to treatment and a lower risk of in-hospital death, intracranial hemorrhage (bleeding in the brain), and an increase in the portion of patients discharged to their home.
REHOVOT, Israel, March 4, 2014 /PRNewswire/ -- D-Pharm Ltd (TASE: DPRM) announced today, March 4th, 2014, the successful interim analysis of the first group of stroke patients
A hands-free ultrasound device combined with a clot-busting drug was safe for ischemic stroke patients in a phase II pilot study.
- Stoppage; cessation (of labor).
- A standing still or idling (of mills, factories, etc.).